PR001 ( DrugBank: - )

2 diseases
告示番号疾患名（ページ内リンク）臨床試験数
6パーキンソン病1
19ライソゾーム病1

6. パーキンソン病

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04127578
(ClinicalTrials.gov)		January 3, 202014/10/2019A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients With Parkinson's Disease With at Least One GBA1 MutationA Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of PR001A in Patients With Parkinson's Disease With at Least One GBA1 MutationParkinson DiseaseBiological: PR001;Drug: Methylprednisolone;Drug: Sirolimus;Drug: Prednisone;Drug: RituximabPrevail TherapeuticsEli Lilly and CompanyRecruiting35 Years80 YearsAll12Phase 1/Phase 2United States;Israel

19. ライソゾーム病

臨床試験数 : 854 /  薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04411654
(ClinicalTrials.gov)		June 29, 202111/5/2020Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose PR001A in Infants With Type 2 Gaucher DiseaseGaucher Disease, Type 2Biological: PR001;Drug: Methylprednisolone;Drug: Sirolimus;Drug: PrednisonePrevail TherapeuticsEli Lilly and CompanyRecruitingN/A24 MonthsAll15Phase 1/Phase 2United States;United Kingdom